138 results match your criteria: "Centre Hospitalier Bretagne Atlantique[Affiliation]"

Introduction: First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty.

View Article and Find Full Text PDF

Background: Appropriate prescription of Proton pump inhibitors (PPIs) remains an important concern amid the rising overuse. A gap exists in the literature regarding the benefit of PPI prophylaxis and the consequences of underprescription in patients at risk for upper gastrointestinal bleeding (UGIB).

Aims: This study aims to describe the characteristics of hemorrhage in relation to PPI use in patients experiencing UGIB, with a focus on high-risk individuals requiring gastroprotection.

View Article and Find Full Text PDF

Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.

Clin Infect Dis

September 2024

Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.

Article Synopsis
  • Researchers investigated the effect of losartan, an angiotensin receptor blocker, on 28-day mortality in hospitalized COVID-19 patients compared to usual care, due to its potential impact on angiotensin levels.
  • The study was stopped early due to safety concerns, showing that adverse events and hypotension were significantly higher in the losartan group (39.8% SAEs and 30.4% hypotension) versus the control group (27.2% SAEs and 15.3% hypotension).
  • There was no significant difference in 28-day mortality (6.5% for losartan vs. 5.9% for usual care), indicating that ARBs should be used cautiously in this patient population to
View Article and Find Full Text PDF

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Lung Cancer

October 2024

Department of Thoracic Oncology, CHU de Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-U1277-CANTHER, Lille, France. Electronic address:

Background: Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of capmatinib are largely unknown. From June 2019, the French Early Access Program (EAP) provided capmatinib to METex14 NSCLC patients who were ineligible for or for whom first-line standard therapies had failed.

View Article and Find Full Text PDF
Article Synopsis
  • Pembrolizumab and nivolumab, two immunotherapy drugs, are used to treat advanced non-small cell lung cancer (NSCLC), and a recent study (IDEE) aimed to assess their safety and effectiveness in real-world conditions.
  • The study included 117 patients, revealing a median age of 67 years, a 79% survival rate at 12 months, and a median time to treatment failure of 9.2 months, with 28% of failures due to toxicity.
  • Overall, the findings suggest that the double-dose regimen is feasible, with no major safety or efficacy concerns identified from the real-life data.
View Article and Find Full Text PDF

Characteristics and outcomes associated with CD2 and CD25 expression on bone marrow mast cells in patients with systemic mastocytosis.

Haematologica

January 2025

Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, F-75015 Paris, France; Hôpital Necker Enfants-Malades, Laboratoire d'Onco-Hématologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.

View Article and Find Full Text PDF

Background: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF).

Methods: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021.

View Article and Find Full Text PDF

Resilience after severe critical illness: a prospective, multicentre, observational study (RESIREA).

Crit Care

July 2024

Laboratoire de Psychologie: Dynamiques Relationnelles Et Processus Identitaires (Psy-DREPI), Université de Bourgogne Franche-Comté, EA7458, Dijon, France.

Background: Critical-illness survivors may experience post-traumatic stress disorder (PTSD) and quality-of-life impairments. Resilience may protect against psychological trauma but has not been adequately studied after critical illness. We assessed resilience and its associations with PTSD and quality of life, and also identified factors associated with greater resilience.

View Article and Find Full Text PDF

Background: The impact of the most recent advances, including targeted therapies and immune checkpoint inhibitors, on early (3-month) mortality in lung cancer is unknown. The aims of this study were to evaluate the real-world rate of and risk factors for early mortality, as well as trends in early mortality over the last 20 years.

Materials And Methods: The KBP prospective observational multicenter studies have been conducted every 10 years since 2000.

View Article and Find Full Text PDF

Sexual dysfunction in cystic fibrosis.

J Cyst Fibros

July 2024

CRCM (Centre de Ressources et de Compétences de la Mucoviscidose), Fondation Ildys, Roscoff, France; Service d'explorations fonctionnelles, Fondation Ildys, Roscoff, France.

Background: Sexual dysfunction (erectile dysfunction in males, sexual dissatisfaction, sexual interest/arousal disorders, and dyspareunia in females) has not been the subject of indepth research in people with cystic fibrosis (CF). This study aimed to determine the prevalence of sexual dysfunction in adults with CF, factors associated with sexual dysfunction, and the impact of sexual dysfunction on quality of life.

Method: We conducted a multicentre study in adults with cystic fibrosis followed in specialist centres in Western France.

View Article and Find Full Text PDF

Assessing the entire landscape of antifungal immune response to COVID-19-associated pulmonary aspergillosis.

Lancet Microbe

August 2024

Rennes University Hospital, Centre National de Référence des Mycoses et Antifongiques LA-AspC Aspergilloses chroniques, European Excellence Center for Medical Mycology (ECMM EC), Laboratoire de Parasitologie-Mycologie, Rennes, France; Univ Rennes, Rennes University Hospital, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail), Rennes, France.

View Article and Find Full Text PDF

An AluYa5 Insertion in the 3'UTR of COL4A1 and Cerebral Small Vessel Disease.

JAMA Netw Open

April 2024

NeuroDiderot, Université Paris Cité, Institut National de la Santé Et de la Recherche Médicale, Unité Mixte de Recherche 1141, Paris, France.

Importance: Cerebral small vessel diseases (CSVDs) account for one-fifth of stroke cases. Numerous familial cases remain unresolved after routine screening of known CSVD genes.

Objective: To identify novel genes and mechanisms associated with familial CSVD.

View Article and Find Full Text PDF

Systemic mastocytosis (SM) corresponds to a rare and heterogeneous spectrum of diseases characterized by the accumulation of atypical mast cells (MCs). Advanced mastocytosis (Adv-SM) is associated with poor survival; in contrast, patients with non-advanced SM (non-Adv-SM) usually have a normal life expectancy but may experience poor quality of life. Despite recent therapeutic progress including tyrosine kinase inhibitors, new treatment options are needed for refractory and/or intolerant patients with both severely symptomatic and Adv-SM.

View Article and Find Full Text PDF

Background And Aims: Systemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been marginally described and accurate histological classification is critical, given the consequences of aggressive SM diagnosis. We aimed to describe the histological features associated with liver SM using updated tools.

View Article and Find Full Text PDF

Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).

Ther Adv Med Oncol

March 2024

Multidisciplinary Oncology and Therapeutic Innovations, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, France.

Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor () mutations. The main objective of this study was to describe, in the real-world setting, these patients' incidence, clinical, and tumoral characteristics.

Methods: The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France.

View Article and Find Full Text PDF

Background: Liver transplant recipients are at risk of tuberculosis, which is particularly difficult-to diagnose and to treat in this population.

Methods: Retrospective study of all cases of tuberculosis diagnosed from 2007 to 2022 in the French network of liver transplant sites.

Results: Twenty-three liver transplant recipients were diagnosed with tuberculosis (six females, median age 59 years [interquartile range, 54-62]), with a median time lapse of 10 months [5-40.

View Article and Find Full Text PDF
Article Synopsis
  • The SEPSISCOOL II trial aims to determine if actively cooling fevered patients in septic shock improves survival and organ function compared to not treating the fever.
  • It is a multicenter, randomized controlled trial involving 820 patients admitted to intensive care units, with the primary endpoint being mortality at day 60.
  • Funded by the French health ministry and approved by an ethics committee, the findings will be shared in peer-reviewed journals upon completion.
View Article and Find Full Text PDF

Background: Recent studies identified coronavirus disease 2019 (COVID-19) as a risk factor for invasive pulmonary aspergillosis (IPA) but produced conflicting data on IPA incidence and impact on patient outcomes. We aimed to determine the incidence and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) in mechanically ventilated patients.

Methods: We performed a multicenter retrospective observational cohort study in consecutive adults admitted to 15 French intensive care units (ICUs) in 2020 for COVID-19 requiring mechanical ventilation.

View Article and Find Full Text PDF

Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study.

Chest

June 2024

Department of Infectious Diseases, University Hospital of Nantes and Centre d'Investigation Clinique 1413, INSERM, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France. Electronic address:

Article Synopsis
  • Pneumocystis jirovecii pneumonia (PcP) has high mortality rates, and the effect of immunocompromising diseases on its severity and outcomes hasn't been thoroughly studied.
  • This retrospective study analyzed 481 patients diagnosed with PcP between 2011 and 2021, revealing that those with immune-mediated inflammatory diseases (IMIDs) or solid tumors had worse survival rates at 90 days.
  • Key factors increasing 90-day mortality included having solid tumors, long-term corticosteroid use, sputum cysts, and higher SOFA scores, with prior corticosteroid therapy, particularly daily prednisone doses ≥10mg, being most impactful among HIV-negative patients.
View Article and Find Full Text PDF

Background: Beta blockers (BBs) are a cornerstone for patients with heart failure (HF) and ventricular dysfunction. However, their use in patients recovering from a cardiogenic shock (CS) remains a bone of contention, especially regarding whether and when to reintroduce this class of drugs.

Methods: FRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers.

View Article and Find Full Text PDF

(1) Background: Bronchial artery embolization has been shown to be effective in the management of neoplastic hemoptysis. However, knowledge of pulmonary artery embolization is lacking. The aim of this study was to evaluate the safety and efficacy of pulmonary artery embolization in patients presenting with hemoptysis related to lung tumors.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare how effective and safe different treatment schedules with azathioprine (AZA) and rituximab (RTX) are in preventing relapses in patients with ANCA-associated vasculitis who are in complete remission.
  • - Researchers conducted trials that compared 18-month fixed RTX to AZA, 18-month fixed RTX to 18-month tailored RTX, and extended 36-month RTX therapy versus placebo, tracking patient outcomes over 84 months.
  • - Findings indicated that the 18-month fixed RTX regimen was significantly better at preventing major relapses compared to AZA and the tailored RTX approach, leading to a higher remission rate at the 84-month mark.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates fluid intake in ICU patients at risk of negative outcomes due to excessive fluid balance, highlighting the need for fluid optimization beyond traditional resuscitation.
  • Conducted across multiple ICUs in France and Spain, it recorded the types and volumes of fluids administered to patients needing vasopressors or invasive ventilation over a 24-hour period.
  • Results indicate that only 36% of the total fluid volume was essential for body fluid homeostasis, with significant variations in fluid administration based on the specific ICU, suggesting a strong center effect on fluid management practices.
View Article and Find Full Text PDF